{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-051852","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2026-08-03T20:14:27+00:00","discovered_at":"2026-08-03T20:16:00.503298+00:00","generated_at":"2026-08-03T20:16:21.796379+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GeneDx Q2 revenue $114.4M, exome/genome volume up 32% YoY; reiterates FY guidance","bullets":["Q2 revenue $114.4M (+11% YoY); exome/genome revenue $100.3M (+17% YoY).","Exome/genome volume 30,785 (+32% YoY); adjusted gross margin 70% (GAAP 68%).","Adjusted net income $0.4M (up $8.6M from Q1); GAAP net loss $17.7M.","Reiterates FY2026 revenue guidance $475-490M with exome/genome volume growth at least 30%.","Amended Blackstone loan: additional $50M term loan (total $150M); Blackstone bought $5M stock at $61/share; pro forma cash ~$188M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-051852","json":"https://secwatch.observer/filing/0001628280-26-051852.json","markdown":"https://secwatch.observer/filing/0001628280-26-051852.md","text":"https://secwatch.observer/filing/0001628280-26-051852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000162828026051852/0001628280-26-051852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000162828026051852/wgs-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T20:16:21.796379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}